Overview
Lutetium 177 vipivotide tetraxetan (LuPSMA) is an advanced radioligand therapy that has expanded treatment options for men with metastatic castration-resistant prostate cancer. However, because LuPSMA is typically used after multiple prior therapies have failed, little is known about what treatments patients receive when their cancer eventually progresses after LuPSMA.
Using the Flatiron Health Research Database, researchers evaluated 743 patients who received LuPSMA, focusing on 161 individuals who went on to initiate a subsequent systemic therapy. The study found that post-LuPSMA care was fragmented, spanning 43 distinct treatment regimens, with chemotherapy being the most common choice. Patients remained on these subsequent therapies for a median of just 2.4 months, achieving a median overall survival of 8.0 months.
Why this matters
This research highlights a major unmet medical need and therapeutic gap for men whose prostate cancer progresses after radioligand therapy. By demonstrating that subsequent treatments offer limited duration and survival benefit, these findings underscore the urgent need to develop novel treatments and clearer sequencing strategies for advanced prostate cancer.